RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Portfolio Pulse from
Aptevo Therapeutics announced that two additional AML patients achieved remission within 30 days in the RAINIER trial using mipletamig in combination with standard care. Overall, 9 out of 10 patients achieved remission with the triplet combination therapy.
March 20, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics' RAINIER trial shows promising results with 9 out of 10 AML patients achieving remission using mipletamig in combination therapy. This could positively impact APVO's stock price.
The announcement of successful remission in 9 out of 10 AML patients using Aptevo's mipletamig in combination therapy is a significant positive development. This success could lead to increased investor confidence and a potential rise in APVO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100